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1. Introduction 
The development of receptor binding techniques 
has greatly assisted in the identification, localisation 
and characterisation of neurotransmitter receptors 
in the central nervous system. This approach has been 
of considerable interest in the case of the dopamine 
receptor since there is evidence that malfunction of 
this neurotransmitter system may relate to certain 
neurological [l] and psychiatric disorders [2] . 
A number of laboratories have reported that [3H] - 
haloperidol binds with high affinity in a saturable 
manner to membranes prepared from cerebral areas 
rich in dopamine, and the potency of a number of 
neuroleptic drugs to displace the high affinity binding 
component of this ligand closely matches their clinical 
efficacy [3-51. However, the specific binding of 
[3H]haloperidol is small (3040% total binding) and 
in our hands preliminary data suggested that this 
neuroleptic binds to more than one population of 
‘specific’ membrane sites. It was felt therefore, that 
this ligand might not be suitable for the accurate 
assessment of binding sites particularly in areas with 
low numbers of dopamine receptors. 
Spiroperidol is more potent than haloperidol in 
its ability to block dopamine receptors, assessed 
behaviourally [6] and biochemically [4] and a recent 
abstract has reported that this neuroleptic binds with 
high affinity to membranes prepared from rat and 
human corpus striatum [7] . In this communication 
we have compared the binding characteristics of this 
new ligand, with those of [3H]haloperidol, to mem- 
branes prepared from various rat cerebral areas. 
2. Materials and methods 
[ 3H] Spiroperidol(26 Ci/mmol) and [ 3H] halo- 
peridol (13 Ci/mmol) were obtained from New 
England Nuclear Co. All other drugs were obtained 
from commercial sources. 
Male Wistar rats (120-l 50 g) were used in all 
experiments. The animals were decapitated, the brain 
removed and dissected on ice as follows. Using the 
point of divergence of the optic nerves as a guide, a 
coronal cut was made 1 mm forward of this, thus 
excising the rostral part of the brain. A further cut 
was made 2 mm caudal to this resulting in a transverse 
slice of tissue. From this slice both the corpora striata 
were removed and, with cuts through both rhinal 
sulci at a tangent to the original position of the striata, 
an area of cortex was separated from the limbic fore- 
brain. The head of the corpus striatum was dissected 
from the rostra1 piece of brain tissue and included 
with that from the slice. 
Tissue was homogenised in 40 vol. ice cold 0.32 M 
sucrose. A crude purification was achieved by an 
initial centrifugation at 1000 X g for 15 min at 4”C, 
the pellet being discarded and the supernatant centri- 
fuged at 50 000 X g for 45 min. This pellet was 
rehomogenised in approx. 10 vol. buffer containing 
15 mM Tris-HCl, pH 7.4,5 mM NazEDTA, 1 .l mM 
ascorbate and 12.5 PM nialamide. The homogenate 
was incubated at 37°C for 15 min and then stored 
at -20°C for future use. 
In the binding assays, membrane suspensions 
(100-600 pg protein) were incubated at 37°C with 
[3H]spiroperidol (0.05-2.0 nM) or [‘Hlhaloperidol 
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(OS-1 6 nM) and appropriate concentration of drug 
under test, in 50 mM Tris-HCl buffer, pH 7.8, in 
final vol. 1 ml for [3H]spiroperidol and 0.5 ml for 
[3H]haloperidol. After 15 min the samples were 
rapidly diluted with 2 ml ice cold buffer and filtered 
under reduced pressure through Whatman glass fibre 
discs (GF/B) and the filters washed with 3 X 4 ml 
buffer. The filters were then shaken with Triton X 
lOO-toluene scintillator, and the radioactivity deter- 
mined by liquid scintillation counting. In every exper- 
iment non-specific binding was determined by mea- 
suring the radioactivity obtained when incubations 
were carried out in the presence of 300 PM dopamine, 
and specific binding was defined as the difference 
between total and non-specific binding. 
3. Results and discussion 
3 .l . Specific binding of [ 3H]haloperidol and L3H/ - 
spiroperidol to membranes from various regions 
of rat brain 
The specific binding of both neuroleptic drugs to 
cerebral membranes was saturable and of high affinity 
while the non-specific component increased linearly 
over the range of ligands used. Specific [3H] spiro- 
peridol binding constituted 80-90% total binding at 
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half saturation in striatal membranes (tig.1). Scatchard 
analysis of the specific binding isotherm yields an 
apparent dissociation constant (Kd) of 0 .14 nM and 
receptor density 0.54 pmol/mg protein. The specific 
binding of [3H]haloperidol, on the other hand, was 
of considerably lower affinity (Kd 2.3 nM) and only 
constituted 30-40% total binding (fig.1). However, 
an almost identical number of binding sites were 
labelled by both dopaminergic ligands in rat striatal 
membranes. 
At concentrations greater than 1.2 nM [‘HIspiro- 
peridol and lo-12 nM [3H]haloperidol, Scatchard 
analysis revealed the presence of lower affinity binding 
sites (figd). This low affinity component was present 
to varying degrees in different brain areas and we are 
at present attempting to evaluate the significance of 
these sites. 
The affinity of [3H]spiroperidol and [3H]halo- 
peridol for membranes prepared from the limbic fore- 
brain, cortex and cerebellum were remarkably similar 
to the respective values for the ligands in the striatum 
(table 1). Moreover, the large regional variation in 
receptor density was reflected by both [3H]neuro- 
leptics suggesting that both ligands bind to the same 
receptor sites. The only disparity in this comparison 
was observed in the limbic forebrain where dopamine 
displacable [3H]spiroperidol binding was greater than 
[3H] haloperidol binding. However, recent experiments 
Non-Specific Binding 
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Fig.1. Binding of [“HI spiroperidol and [‘HI haloperidol to rat corpus striatum membranes. Tissue was incubated with increasing 
concentrations of “H-labelled ligand. Non-specific binding is that observed in the presence of 300 PM dopamine. Binding in the 
absence of 300 PM dopamine less the nonspecific binding represents pecific binding. 
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F&.2. Scatchard analysis of [ 3H] spiroperidol and [‘HI haloperidol binding to rat corpus striatum membranes. Points have been 
plotted from the data in fig.1. 
(in preparation) suggest hat whereas in cortex and 
striatum dopamine maximally displaces [3H]spiro- 
peridol to the same degree as competing cold neuro- 
leptics, this catecholamine inhibits binding to a greater 
extent than neuroleptics in the limbic forebrain. The 
nature of this discrepancy remains to be established. 
3.2. Phamacologikal characterisation of [3H]neuro- 
lep tic binding sites 
Specific binding of [3H]spiroperidol and [‘HIhalo- 
peridol to striatal membranes was displaced by low 
concentrations of neuroleptic drugs. This displacement 
was stereospecific for flupenthixol and butaclamol, 
a-(cis)-flupenthixol and (+)-butaclamol being consider- 
ably more potent than P-(trans)-flupenthixol and 
(-)-butaclamol, respectively (fig.3). Spiroperidol was 
the most potent drug in its ability to displace specific 
[‘Hlspiroperidol binding and the affinity constants 
(Ki) for this drug and haloperidol agree well with their 
dissociation constants &) obtained by direct binding. 
The relative potencies of the other neuroieptics to 
compete for [3H]spiroperidol binding sites in rat 
striatum (table 2) are more or less identical with those 
obtained against [‘Hlhaloperidol by ourselves (not 
shown) and by other workers [3,4] and bear a good 
correlation with the clinical potencies of the neuro- 
leptics [3] . a and 0 Adrenoceptor antagonists were 
considerably weaker than the neuroleptics and of the 
agonists apomorphine and dopamine were more 
potent than noradrenaline and isoprenaline (table 2). 
Table 1 
Affinity and regional distribution of [3H]spiroperidol and [jH] haloperidol 
binding to rat cerebral membranes 
[‘HI Spiroperidol binding [ ‘H]Haloperidol binding 
Kd 
(nM) 
B max Kd Bmax 
(pmol . mg protein-’ ) (nM) (pmol . mg protein-’ ) 
Corpus striatum 0.14 0.54 2.2 0.48 
Limbic forebrain 0.12 0.29 2.3 0.16 
Cortex 0.15 0.23 2.3 0.24 
Cerebellum 0.27 0.06 2:3 0.04 
Data was calculated by Scatchard analysis from triplicate determinations 
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Fig.3. Competition for [‘HI spiroperidol and [‘HI haloperidol binding sites on rat striatal membranes. Increasing concentrations 
of each non-radioactive drug were added to tubes containing approx. 0.5 nM [ sH] spiroperidol or 4 nM [sH] haloperidol. Specific 
binding is that which was displaced by 300.&f dopamine. Each point is the mean of duplicate determinations. 
Table 2 
Drug inhibition of [‘Hlspiroperidol and [sH]haloperidol binding to rat striatal 
membranes 
Drug Ki (nM) 
Spiroperidol 
(+)-Butaclamol 
cY-Flupenthixol 
Fluphenazine 
Haloperidol 
Trifluperazine 
Thioridazine 
P-Flupenthixol 
Cyproheptadine 
Apomorphine 
(-)-Butaclamol 
Dopamine 
Phentolamine 
(+) or (-) Propranolol 
(-)-Noradrenaline 
Isoprenaline 
Clonidine 
Metiamide 
0.29 t 0.03 
0.80 f 0.09 
0.90+ 0.09 
2.0 f 0.3 
2.2 c 0.2 
4.4 * 0.5 
9.8 f 1.4 
45 f 7 
60 f 8 (2) 
140 i 18 
500 + 90 
1200 f 160 
1900 f 230 
5000 + 650 
10000 k1600 
>100000 f (2) 
>100000 r (1) 
>100000 ?: (1) 
Membranes were incubated with at least 5 concentrations of drug and the Ki 
value calculated from the equation Ki = IC,,/(l + S/Kd), where ICC,, is the con- 
centration of drug required to inhibit specific binding by 50%, s is the concentra- 
tion of radioactive ligand (approx. 0.5 mM [sH]spiroperidol) and Kd is the dis- 
sociation constant. Results are means * standard errors for 3 experiments, 
except where indicated 
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4. Conclusions Acknowledgements 
It appears from the binding properties, regional 
distribution and pharmacological characterisation, 
that [3H]spiroperidol and [3H]haloperidol bind to 
identical sites in rat brain. Moreover, as suggested 
previously, the distribution of the binding sites and 
potencies of dopaminergic agonists and antagonists 
indicate that the specifically labelled sites are closely 
associated with the ‘dopamine receptor’. Thus the 
sites show a crude correlation with the degree of 
dopaminergic innervation in the different cerebral 
regions with the striatum showing the greatest enrich- 
ment of binding sites and the cerebellum the least. 
The appreciable number of receptors found in the 
area of cortex used in this study possibly relates to 
the supragenual and suprarhinal dopaminergic systems 
described [8] . 
The authors would like to thank the Wellcome 
Trust for financial support and Miss Jenny Bell for 
preparing the manuscript. 
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